Stock NNVC NANOVIRICIDES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NanoViricides, Inc.

Equities

NNVC

US6300873022

Delayed Nyse
Other stock markets
 11:16:57 2024-05-01 am EDT 		5-day change 1st Jan Change
1.21 USD +0.83% Intraday chart for NanoViricides, Inc. +5.22% +18.63%
Apr. 30 NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon CI
Feb. 14 NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Evolution of the average Target Price on NanoViricides, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1c56a8.BVluuoZZs60exeyS_K1mBmiXXEOaYbmil2Jvh5fwqqo.ZBQqw_Ee399cs6T6jJpUcS_RBBvNGODL9BQM9vmJ_91MKAmP5TLH8mi_gw~08e4e185b91bb30ab3dca630fcb9f5d2

Analyst Recommendations on NanoViricides, Inc.

EF Hutton Lowers Price Target on NanoViricides to $5.25 From $8.50, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.2 USD
Average target price
6.5 USD
Spread / Average Target
+441.67%
High Price Target
6.5 USD
Spread / Highest target
+441.67%
Low Price Target
6.5 USD
Spread / Lowest Target
+441.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NanoViricides, Inc.

EF Hutton

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NNVC Stock
  4. Consensus NanoViricides, Inc.